Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4533MR)

This product GTTS-WQ4533MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4533MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11469MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ4208MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ10590MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ15299MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ1220MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ12870MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ12652MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ7184MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW